Literature DB >> 32803707

Assessment of 1 mg Dexamethasone Suppression Test in Patients with Obesity Before Bariatric Surgery.

Dilek Gogas Yavuz1, Tugce Apaydin2, Hatice Gizem Gunhan3, Meliha Melin Uygur4.   

Abstract

PURPOSE: This study aims to examine the prevalence of Cushing's syndrome (CS) in class 3 obese patients before bariatric surgery.
MATERIALS AND METHODS: The data of 1037 class 3 obese patients admitted to the endocrinology outpatient clinic for endocrinological evaluation before bariatric surgery between 2012 and 2019were reviewed retrospectively. One milligram dexamethasone suppression test (DST) was used for the evaluation of hypercortisolism in all cases and cutoff accepted as 1.8 μg/dL.
RESULTS: The mean body mass index (BMI) was 48 ± 8.9 kg/m2 and age was 42 ± 10 years with female preponderance (F/M: 799/238] being observed in this cohort. Insufficient cortisol suppression was found in 40 patients; confirmed hypercortisolemia was detected in 8 patients. The prevalence of pathologic DST was 3.85% and 0.77% in confirmed hypercortisolism. The specificity for 1-mg DST with the cutoff 1.8 μg/dL was calculated as 96.8%.
CONCLUSION: Hypercortisolism prevalence was found to be low, and 1 mg DST is a sufficient test for the screening of CS in class 3 obese patients evaluated before bariatric surgery.

Entities:  

Keywords:  Cushing’s syndrome; Hypercortisolism; Morbid obesity

Mesh:

Substances:

Year:  2020        PMID: 32803707     DOI: 10.1007/s11695-020-04865-x

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  2 in total

Review 1.  Alcohol-induced Cushing syndrome. Hypercortisolism caused by alcohol abuse.

Authors:  F Besemer; A M Pereira; J W A Smit
Journal:  Neth J Med       Date:  2011 Jul-Aug       Impact factor: 1.422

Review 2.  The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states.

Authors:  J Newell-Price; P Trainer; M Besser; A Grossman
Journal:  Endocr Rev       Date:  1998-10       Impact factor: 19.871

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.